WEST Search History

DATE: Thursday, May 01, 2003

Set Name side by side	Query	Hit Count	Set Name result set
	DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR		
L24	L23 and @ad<19951115	176	L24
L23	L12 and ((interferon-gamma or interferon adj gamma or IFN-gamma or IFM adj gamma).ab. or (interferon-gamma or interferon adj gamma or IFN-gamma or IFM adj gamma).ti.)	176	L23
L22	255 L14 L13 L12 and ((interferon-gamma or interferon adj gamma or IFN-gamma or IFM adj gamma).ab. or (interferon-gamma or interferon adj gamma or IFN-gamma or IFM adj gamma).ti.)	189885	L22
L21	L20 and (treat$5 inhibit$5 prevent$6 therap$8 pharma$8) with (interferon-gamma or interferon adj gamma or IFN-gamma or IFM adj gamma or inflam$8)	66	L21
L20	L19 and @ad<19951115	80	L20
L19	(interferon-gamma or interferon adj gamma or IFN-gamma or IFM adj gamma) with inflam$8	506	L19
L18	(interferon-gamma or interferon adj gamma or IFN-gamma or IFM adj gamma) same inflam$8	1147	L18
L17	L16 and @ad<19951115	27	L17
L16	(Il-12 or il adj 12 or interleukin adj 12 or interleukin-12) same (interferon-gamma or interferon adj gamma or IFN-gamma or IFM adj gamma) and (treat$6 therap$8 pharma$8) with (Il-12 or il adj 12 or interleukin adj 12 or interleukin-12)	475	L16
L15	l14 and Il-12	13	L15
L14	l13 and l11	255	L14
L13	L12 and (interferon-gamma or interferon adj gamma or IFN-gamma or IFM adj gamma).ab. or (interferon-gamma or interferon adj gamma or IFN-gamma or IFM adj gamma).ti.	402	L13
L12	L11 and @ad<19951115	465	L12
L11	(interferon-gamma or interferon adj gamma or IFN-gamma or IFM adj gamma) with (treat$6 therap$8 pharma$8)	1624	L11
L10	(interferon-gamma or interferon adj gamma or IFN-gamma or IFM adj gamma) (s) (treat$6 therap$8 pharma$8)	7023402	L10
L9	(interferon-gamma or interferon adj gamma) (s) (treat$6 therap$8 pharma$8)	7023377	L9
L8	L5 and @ad<20001121	45	L8
L7	L5 and @ad<20011121	49	L7
L6	L5 and @ad<2001121	0	L6
L5	l3 not l4	53	L5

L4	L3 and @pd>20021015	17	L4
L3	L2 and l1	70	L3
L2	(IGIF IL-18 or IL adj 18 or interleukin adj 18 or interleukin-18 (interferon-gamma or interferon adj gamma or IFN-gamma) adj inducing).ab.	143	L2
L1	(IGIF IL-18 or IL adj 18 or interleukin adj 18 or interleukin-18 (interferon-gamma or interferon adj gamma or IFN-gamma) adj inducing).ti.	89	L1

END OF SEARCH HISTORY

1: S60226. cytokine IGIF - m...[gi:2137253] BLink, Domains, Links

```
LOCUS       S60226                  192 aa            linear   ROD 20-JUN-2000
DEFINITION  cytokine IGIF - mouse.
ACCESSION   S60226
VERSION     S60226  GI:2137253
DBSOURCE    pir: locus S60226;

            summary: #length 192 #molecular-weight 22135 #checksum 3140
            ;
            superfamily: Mus musculus cytokine IGIF
            ;
            PIR dates: 10-Apr-1996 #sequence_revision 19-Apr-1996 #text_change
            20-Jun-2000

KEYWORDS    .
SOURCE      Mus musculus (house mouse)
  ORGANISM  Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1  (residues 1 to 192)
  AUTHORS   Okamura,H., Tsutsui,H., Komatsu,T., Yutsudo,M., Hakura,A.,
            Tanimoto,T., Torigoe,K., Okura,T., Nukada,Y., Hattori,K., Akita,K.,
            Namba,M., Tanabe,F., Konishi,K., Fukuda,S. and Kurimoto,M.
  TITLE     Cloning of a new cytokine that induces IFN-gamma production by T
            cells
  JOURNAL   Nature 378 (6552), 88-91 (1995)
  MEDLINE   96061009
   PUBMED   7477296
FEATURES             Location/Qualifiers
     source          1..192
                     /organism="Mus musculus"
                     /db_xref="taxon:10090"
     Protein         1..192
                     /product="cytokine IGIF"
ORIGIN
        1 maamsedscv nfkemmfidn tlyfipeeng dlesdnfgrl hcttavirni ndqvlfvdkr
       61 qpvfedmtdi dqsasepqtr liiymykdse vrglavtlsv kdskmstlsc knkiisfeem
      121 dppeniddiq sdliffqkrv pghnkmefes slyeghflac qkeddafkli lkkkdengdk
      181 svmftltnlh qs
//
```

FILE 'HOME' ENTERED AT 13:57:52 ON 01 MAY 2003

L1 29121 (INTERFERON-GAMMA OR INTERFERON (N) GAMMA OR IFN-GAMMA OR IFN (A) GAMMA) (S) (PHARMA########## OR THERAP##### OR TREAT####)

(FILE 'HOME' ENTERED AT 13:57:52 ON 01 MAY 2003)

FILE 'STNGUIDE' ENTERED AT 13:58:13 ON 01 MAY 2003

FILE 'HOME' ENTERED AT 13:58:17 ON 01 MAY 2003

FILE 'STNGUIDE' ENTERED AT 13:58:31 ON 01 MAY 2003

FILE 'MEDLINE, CAPLUS, BIOSIS' ENTERED AT 13:58:48 ON 01 MAY 2003

L1	29121	S (INTERFERON-GAMMA OR INTERFERON (N) GAMMA OR IFN-GAMMA OR IFN
L2	2635	S L1 AND (IL-12 OR IGIF OR IL-18)
L3	1657	S L2 NOT PY>2000
L4	227	S L2 NOT PY>1995
L5	118	DUP REM L4 (109 DUPLICATES REMOVED)
L6	0	S L5 AND (IL-12 SAME IGIF)
L7	0	S L5 AND (IL-12 SAME IL-18)
L8	0	S L5 AND IL-12 SAME IFN-GAMMA
L9	118	S L5 AND IL-12

L9 ANSWER 20 OF 118 MEDLINE
TI **IL-12**-induced protection against blood-stage Plasmodium chabaudi AS requires IFN-gamma and TNF-alpha and occurs via a nitric oxide-dependent mechanism.
AU Stevenson M M; Tam M F; Wolf S F; Sher A
SO JOURNAL OF IMMUNOLOGY, (1995 Sep 1) 155 (5) 2545-56.
Journal code: 2985117R. ISSN: 0022-1767.

L9 ANSWER 21 OF 118 MEDLINE
TI **IL-12** stimulates an antiviral type 1 cytokine response but lacks adjuvant activity in IFN-gamma-receptor-deficient mice.
AU Schijns V E; Haagmans B L; Horzinek M C
SO JOURNAL OF IMMUNOLOGY, (1995 Sep 1) 155 (5) 2525-32.
Journal code: 2985117R. ISSN: 0022-1767.

L9 ANSWER 24 OF 118 MEDLINE
TI **IL-12** prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN-gamma.
AU Zhou P; Sieve M C; Bennett J; Kwon-Chung K J; Tewari R P; Gazzinelli R T; Sher A; Seder R A
SO JOURNAL OF IMMUNOLOGY, (1995 Jul 15) 155 (2) 785-95.
Journal code: 2985117R. ISSN: 0022-1767.

L9 ANSWER 30 OF 118 MEDLINE
TI The stimulatory effects of interleukin (**IL**)-**12** on hematopoiesis are antagonized by **IL-12**-induced interferon gamma in vivo.
AU Eng V M; Car B D; Schnyder B; Lorenz M; Lugli S; Aguet M; Anderson T D; Ryffel B; Quesniaux V F
SO JOURNAL OF EXPERIMENTAL MEDICINE, (1995 May 1) 181 (5) 1893-8.
Journal code: 2985109R. ISSN: 0022-1007.

39 OF 118 MEDLINE
TI In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS).
AU Gazzinelli R T; Giese N A; Morse H C 3rd
SO JOURNAL OF EXPERIMENTAL MEDICINE, (1994 Dec 1) 180 (6) 2199-208.
Journal code: 2985109R. ISSN: 0022-1007.

L9 ANSWER 42 OF 118 MEDLINE
TI In vivo augmentation of IFN-gamma with a rIL-12 human/mouse chimera: pleiotropic effects against infectious agents in mice and rats.
AU Gladue R P; Laquerre A M; Magna H A; Carroll L A; O'Donnell M; Changelian P S; Franke A E
SO CYTOKINE, (1994 May) 6 (3) 318-28.
Journal code: 9005353. ISSN: 1043-4666.

L9 ANSWER 44 OF 118 MEDLINE
TI Recombinant **IL-12** administration induces tumor regression in association with IFN-gamma production.
AU Nastala C L; Edington H D; McKinney T G; Tahara H; Nalesnik M A; Brunda M J; Gately M K; Wolf S F; Schreiber R D; Storkus W J; +
SO JOURNAL OF IMMUNOLOGY, (1994 Aug 15) 153 (4) 1697-706.
Journal code: 2985117R. ISSN: 0022-1767.

L9 ANSWER 45 OF 118 MEDLINE
TI Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha.

AU Hunter C A; Subauste C S; Van Cleave V H; Remington J S
SO INFECTION AND IMMUNITY, (1994 Jul) 62 (7) 2818-24.
Journal code: 0246127. ISSN: 0019-9567.

L9 ANSWER 51 OF 118 MEDLINE
TI Effects of **IL-12** on helper T cell-dependent immune responses in vivo.
AU McKnight A J; Zimmer G J; Fogelman I; Wolf S F; Abbas A K
SO JOURNAL OF IMMUNOLOGY, (1994 Mar 1) 152 (5) 2172-9.
Journal code: 2985117R. ISSN: 0022-1767.

L9 ANSWER 86 OF 118 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI **IL-12** is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis.
AU Scharton-Kersten, Tanya; Afonso, Luis C. C.; Wysocka, Maria; Trinchieri, Giorgio; Scott, Phillip (1)
SO Journal of Immunology, (1995) Vol. 154, No. 10, pp. 5320-5330.
ISSN: 0022-1767.

L9 ANSWER 91 OF 118 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI Antitumor effects of interleukin-12 (**IL-12**): Applications for the immunotherapy and gene therapy of cancer.
AU Tahara, H.; Lotze, M. T. (1)
SO Gene Therapy, (1995) Vol. 2, No. 2, pp. 96-106.
ISSN: 0969-7128.

L9 ANSWER 97 OF 118 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice.
AU Trembleau, Sylvie; Penna, Giuseppe; Bosi, Emmanuele; Mortara, Anna; Gately, Maurice K.; Adorini, Luciano (1)
SO Journal of Experimental Medicine, (1995) Vol. 181, No. 2, pp. 817-821.
ISSN: 0022-1007.

L9 ANSWER 102 OF 118 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI **IL-12** is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis.
AU Romani, Luigina (1); Mencacci, Antonella; Tonnetti, Laura; Spaccapelo, Roberta; Cenci, Elio; Puccetti, Paolo; Wolf, Stanley F.; Bistoni, Francesco
SO Journal of Immunology, (1994) Vol. 153, No. 11, pp. 5167-5175.
ISSN: 0022-1767.

L9 ANSWER 114 OF 118 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI Antitumor and antimetastatic activity of interleukin 12 against murine tumors.
AU Brunda, Michael J. (1); Luistro, Leopoldo; Warrier, Rajeev R.; Wright, Rosemary B.; Hubbard, Brian R.; Murphy, Molly; Wolf, Stanley F.; Gately, Maurice K.
SO Journal of Experimental Medicine, (1993) Vol. 178, No. 4, pp. 1223-1230.
ISSN: 0022-1007.

L9 ANSWER 115 OF 118 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI Resolution of cutaneous leishmaniasis: Interleukin 12 initiates a protective T helper type 1 immune response.
AU Sypek, Joseph P. (1); Chung, Charles L.; Mayor, Sharon E. H.; Subramanyam, Janaki M.; Goldman, Samuel L.; Sieburth, Derek S.; Wolf, Stanley F.; Schaub, Robert G.
SO Journal of Experimental Medicine, (1993) Vol. 177, No. 6, pp. 1797-1802.
ISSN: 0022-1007.

L9 ANSWER 116 OF 118 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI Purification of a factor which provides a costimulatory signal for gamma interferon production.
AU Nakamura, Kyohshi (1); Okamura, Haruki; Nagata, Kumiko; Komatsu, Toshinori; Tamura, Toshihide
SO Infection and Immunity, (1993) Vol. 61, No. 1, pp. 64-70.
ISSN: 0019-9567.

L9 ANSWER 21 OF 118 MEDLINE
AN 95378675 MEDLINE
DN 95378675 PubMed ID: 7650382
TI **IL-12** stimulates an antiviral type 1 cytokine response but lacks adjuvant activity in IFN-gamma-receptor-deficient mice.
AU Schijns V E; Haagmans B L; Horzinek M C
CS Department of Infectious Diseases and Immunology, Veterinary Faculty, Ultrecht University, The Netherlands.
SO JOURNAL OF IMMUNOLOGY, (1995 Sep 1) 155 (5) 2525-32.
Journal code: 2985117R. ISSN: 0022-1767.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 199509
ED Entered STN: 19951005
Last Updated on STN: 19951005
Entered Medline: 19950922
AB Cytokines can be used as adjuvants to enhance and direct protective immune responses induced by vaccines. **IL-12**, a cytokine that favors the maturation of Th1-type cells and stimulates associated cell-mediated responses was evaluated as immunologic adjuvant for a viral vaccine in a mouse challenge model. When it was administered together with inactivated pseudorabies virus, a herpes simplex virus related alpha-herpesvirus, increased production of IFN-gamma by ex vivo-stimulated splenocytes was observed as well as augmented production of antiviral serum lgG2a. This was associated with increased protection against a lethal challenge infection. Infection of **IfN-gamma** -neutralizing Ab reduced the increased antiviral resistance in **IL -12-treated** mice. Also, in mice bearing an inactivated IFN-gamma-receptor gene **IL-12** failed to stimulate protection against challenge and the synthesis of antiviral lgG2a. However, in these IFN-gamma-receptor knockout mice, increased antiviral lgG2b levels and enhanced IFN-gamma-secretion, with minimal IL-4 production, by ex vivo-stimulated splenocytes was observed. In wild-type mice administration of recombinant IFN-gamma but not IL-2 mimicked the immune-stimulating activity of **IL-12**; it is therefore likely that the **IL-12** adjuvant activity is largely mediated by physiologic IFN-gamma.

L9 ANSWER 30 OF 118 MEDLINE
AN 95239133 MEDLINE
DN 95239133 PubMed ID: 7722464
TI The stimulatory effects of interleukin (**IL**)-**12** on hematopoiesis are antagonized by **IL-12**-induced interferon gamma in vivo.
AU Eng V M; Car B D; Schnyder B; Lorenz M; Lugli S; Aguet M; Anderson T D; Ryffel B; Quesniaux V F
CS Institute of Toxicology, Swiss Federal Institute of Technology, Schwerzenbach.
SO JOURNAL OF EXPERIMENTAL MEDICINE, (1995 May 1) 181 (5) 1893-8.
Journal code: 2985109R. ISSN: 0022-1007.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199505
ED Entered STN: 19950605
Last Updated on STN: 19950605

Entered Medline: 19950525

AB Interleukin (**IL**)-**12** synergizes with other cytokines to stimulate the proliferation and differentiation of early hematopoietic progenitors in vitro. However, in vivo administration of **IL-12** decreases peripheral blood counts and bone marrow hematopoiesis. Here, we used interferon (IFN) gamma receptor-deficient (IFN gamma R-/-) mice to investigate whether the in vivo inhibition of hematopoiesis by **IL-12** is indirectly mediated by **IL-12**-induced IFN-gamma. **IL-12** administered for 4 d (1 microgram/mouse per day) resulted in lower peripheral blood counts and a 2-fold decrease in bone marrow cellularity in wild-type mice, but not in IFN gamma R-/- mice. Bone marrow hematopoietic progenitors were decreased after **IL-12** **treatment** in wild-type mice, but rather increased in **IFN** **gamma** R-/- mice. Splenic cellularity was 2.3-fold higher after **IL-12** administration in wild-type mice, largely due to natural killer (NK) cell and macrophage infiltration together with some extramedullary hematopoiesis. In IFN gamma R-/- mice, spleen cellularity was less increased, there were fewer infiltrating NK cells, but a strong extramedullary hematopoiesis. Thus, alterations mediated by **IL-12**-induced IFN-gamma include reduction in bone marrow cellularity and hematopoietic progenitors, as well as pronounced splenomegaly, largely caused by NK cell infiltration. In the absence of IFN-gamma signaling, **IL-12** promotes hematopoiesis, consistent with its in vitro activities.

L9 ANSWER 39 OF 118 MEDLINE
AN 95053754 MEDLINE
DN 95053754 PubMed ID: 7964495
TI In vivo treatment with interleukin 12 protects mice from immune abnormalities observed during murine acquired immunodeficiency syndrome (MAIDS).
AU Gazzinelli R T; Giese N A; Morse H C 3rd
CS Section of Immunobiology and Cell Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892.
NC NO1 AI-45203 (NIAID)
SO JOURNAL OF EXPERIMENTAL MEDICINE, (1994 Dec 1) 180 (6) 2199-208. Journal code: 2985109R. ISSN: 0022-1007.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals; AIDS
EM 199412
ED Entered STN: 19950110
Last Updated on STN: 19950110
Entered Medline: 19941223

AB Lymphoproliferation, chronic B cell activation resulting in hypergammaglobulinemia, and profound immunodeficiency are prominent features of a retrovirus-induced syndrome designated murine acquired immunodeficiency syndrome (MAIDS). In vivo treatment of infected mice with recombinant interleukin 12 (**IL-12**) beginning at the time of infection or up to 9 wk after virus inoculation markedly inhibited the development of splenomegaly and lymphadenopathy, as well as B cell activation and Ig secretion. **Treatment** with **IL** **-12** also had major effects in preventing induction of several immune defects including impaired production of **interferon** **gamma** (**IFN-gamma**) and IL-2 and depressed proliferative responses to various stimuli. The therapeutic effects of **IL-12** on the immune system of mice with MAIDS were also associated with reduced expression of the retrovirus that causes this

disease (BM5def), with lesser effects on expression of ecotropic MuLV. **IL-12 treatment** was not effective in **IFN-gamma** knockout mice or in infected mice **treated** simultaneously with **IL-12** and anti-**IFN-gamma**. These results demonstrate that induction and progression of MAIDS are antagonized by **IL-12** through high-level expression of IFN-gamma and may provide an experimental basis for developing treatments of retrovirus-induced immune disorders with similar immunopathogenic mechanisms.